Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Boehringer appoints new chairman of the board

Hubertus vonBaumbach will succeed Andreas Barner

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

- PMLiVE

Boehringer’s Praxbind granted accelerated approved by FDA

Reversal agent for anticoagulant Pradaxa given the nod

Boehringer Ingelheim headquarters

Boehringer and Philogen collaborate on acute myeloid leukaemia

Hope to bring new therapies for the rare disease

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

- PMLiVE

Boehringer hails its ‘landmark year’ in respiratory

Marketing and sales head Allan Hillgrove on the company's recent efforts

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

- PMLiVE

Boehringer Ingelheim’s John Pugh set for move to Accenture

Will take up London-based role in theconsultants' digital department

- PMLiVE

Sharing knowledge to combat emerging threats

'One health' advocates say closer cooperation between human and animal medicine firms could offer new solution

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

- PMLiVE

Making savings from European drugs budgets

National programmes of cuts are the order of the day

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links